Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)

Trial Profile

Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Interim results (n=62, data cut off: 1 Oct 2015) presented at The 99th Annual Meeting of the Endocrine Society
    • 02 Mar 2016 Planned End Date changed from 1 Mar 2024 to 1 Apr 2024, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top